Something in those regions is different, but they don't yet know what.
On an island where a debilitating and incurable disease has long moved largely unseen, Puerto Rico has built its first systematic record of amyotrophic lateral sclerosis — and the map it reveals is uneven in ways that demand explanation. Between one and two residents per 100,000 develop ALS each year, a rate familiar to epidemiologists worldwide, yet two regions, Arecibo and Caguas, carry a disproportionate burden that points toward something local and still unnamed. Researchers are now tracing the threads of environment, genetics, and social circumstance, understanding that for a disease without a cure, the discipline of careful observation is itself a moral act.
- Two regions of Puerto Rico are showing ALS case concentrations far beyond what their populations would statistically predict, signaling that localized risk factors — environmental, genetic, or social — may be at work.
- Younger patients, some in their twenties, are falling into a diagnostic blind spot: because ALS rarely enters a clinician's mind for a 27-year-old, years can pass between first symptoms and a name for the illness, eroding precious time for treatment and planning.
- Men are developing ALS at roughly twice the rate of women, and a possible link to asthma — largely undocumented in global literature — has emerged among Puerto Rican patients, opening new biological questions.
- Researchers are investigating whether a pattern of unexplained falls before diagnosis could serve as an early clinical alarm, potentially compressing the long and damaging gap between symptom onset and specialist care.
- Puerto Rico's registry, launched in 2022, is still young, but it is already reframing the disease from an invisible tragedy into a mappable, investigable public health challenge — with the geographic clustering in Arecibo and Caguas now at the center of that investigation.
Puerto Rico's first systematic ALS registry has produced a finding that is both reassuring and unsettling. The island's incidence rate — one to two new cases per 100,000 residents each year — aligns with what epidemiologists observe across the United States and Europe. But the geography refuses to behave. The regions of Arecibo and Caguas are generating far more cases than their populations would suggest, and that clustering has become the central question driving Dr. France Aponte and her research team.
The registry began in 2022, anchored to a specialized multidisciplinary clinic at the Medical Sciences Campus. Its founding purpose was elemental: establish where ALS appears in Puerto Rico, which communities carry the greatest burden, and what forces might be shaping its distribution. Aponte has been careful to note that rising diagnoses likely reflect improved clinical recognition rather than a true surge in the disease itself.
The patient data reveals a disease of contradictions. Most cases follow the expected pattern — patients over 50, more men than women, at roughly a two-to-one ratio. But the registry has also captured patients in their late twenties and early thirties, and these younger individuals face a cruel delay. When a 27-year-old presents with weakness, ALS rarely enters the differential diagnosis. Aponte described cases where symptoms began in the early twenties but a diagnosis didn't arrive until five or six years later — time lost to treatment, to preparation, to understanding.
Among comorbidities, hypertension and diabetes appear frequently, reflecting broader health patterns on the island. More striking is a possible association with asthma, a connection poorly documented in the international literature and one whose biological meaning, if any, remains unresolved.
The disease itself offers no mercy. It dismantles the motor neurons that animate muscle, leaving patients unable to move, breathe, or swallow as it progresses. Aponte's team is now examining whether recurrent falls in the period before diagnosis might serve as an early warning signal — a clinical cue that could prompt faster specialist referral and shorten the diagnostic odyssey.
The deeper mystery remains in Arecibo and Caguas. Investigators are examining environmental exposures, genetic inheritance, and the social determinants of health — poverty, housing conditions, access to care — searching for whatever distinguishes these regions from the rest of the island. The answer is not yet within reach. But the act of searching, methodically and openly, represents something meaningful for a disease that has taken so many lives and surrendered none of its secrets.
Puerto Rico now has its first systematic count of amyotrophic lateral sclerosis cases, and the numbers are telling researchers something unexpected. Between one and two people per 100,000 residents develop ALS each year on the island—a rate that tracks with what epidemiologists see in the United States and Europe. But the geography is strange. Two regions, Arecibo and Caguas, are showing up with far more cases than their populations would predict. That clustering is what has Dr. France Aponte and her team digging deeper.
The registry itself is young. It started in 2022, drawing patients from the specialized multidisciplinary clinic at the Medical Sciences Campus. The point was straightforward: find out where ALS lives in Puerto Rico, which populations might be at higher risk, and what factors might be driving it. For a disease that remains incurable and whose cause remains largely mysterious, even basic epidemiology feels like progress. Aponte explained to researchers that the apparent rise in diagnoses doesn't necessarily mean ALS is becoming more common—it means doctors and communities are getting better at spotting it.
What the data shows so far is a disease that doesn't follow a simple pattern. Most patients are over 50, which matches what happens elsewhere. But the registry has also caught cases in people in their late twenties and early thirties, and those younger patients face a particular trap: ALS doesn't occur to most doctors when a 27-year-old walks in with weakness. Aponte described cases where symptoms began in the early twenties but diagnosis didn't come until five or six years later. That delay matters. It means lost time for treatment, for planning, for understanding what's happening to your body.
Men are getting sick at roughly twice the rate of women—a pattern that shows up in international studies too, though nobody yet understands why. The researchers are also finding that hypertension and diabetes are common in their ALS patients, which tracks with what's common in Puerto Rico generally. More intriguingly, they've found a possible link to asthma, something that hasn't been well documented in the broader medical literature. Whether there's a biological mechanism connecting them, or whether it's coincidence, remains an open question.
The disease itself is relentless. It attacks the motor neurons that tell muscles what to do. Some patients lose the ability to move, falling frequently, their strength draining week by week. Others can't breathe properly or can't swallow. Aponte and her colleagues are now investigating whether a pattern of falls before diagnosis might become an early warning sign—something that could push a doctor to think of ALS sooner. She's recommending that anyone with progressive weakness, movement problems, breathing difficulties, or swallowing trouble see their primary care doctor and ask for a specialist evaluation if needed.
The real puzzle remains Arecibo and Caguas. The researchers are looking at environmental exposures, genetic factors, and the social determinants of health—poverty, housing, access to care. Something in those regions is different. Whether it's something in the water or soil, something in the genes of the people who live there, or something about how people live, the investigators don't yet know. But they're looking. For a disease that has killed so many and cured none, even the act of looking carefully is a form of hope.
Notable Quotes
We're estimating roughly one to two cases per hundred thousand people of new cases— Dr. France Aponte, epidemiologist and CHALS-CCT study coordinator
We've seen cases where symptoms begin at 22 or 23 years old and diagnosis doesn't come until five or six years later— Dr. France Aponte
The Hearth Conversation Another angle on the story
Why does it matter that Puerto Rico now has a registry? Couldn't they just count cases as they came in?
Because you can't see patterns in noise. A registry is systematic—it catches cases that might otherwise be scattered across different hospitals, different doctors, different islands of the healthcare system. You get a real picture of who's sick and where.
And what they found is that two regions have more cases than expected. What does that tell you?
It tells you something is there. Not random. Something about Arecibo and Caguas is different from the rest of the island. Could be environmental—something in the air, the water, the soil. Could be genetic clustering. Could be how people live. But it's not chance.
The younger patients—the ones diagnosed in their late twenties—that seems like it should be easier to catch, not harder.
You'd think so. But ALS is rare enough that when a young person comes in weak, a doctor thinks of a hundred other things first. Lyme disease, thyroid problems, depression. By the time someone thinks of ALS, years have passed. That delay changes everything about what the disease does to you.
Why are men getting it twice as often as women?
That's the question nobody can answer yet. It shows up the same way everywhere—men get it more—but the why is still dark. Genetic? Occupational exposure? Something about how male and female bodies respond to the same insult? They're still looking.
The asthma connection seems random.
It probably isn't. The researchers found it, which means it's real in their data. Whether it's causal or just correlation, whether there's a shared mechanism or just shared risk factors, that's what they're trying to untangle now. That's how you move from mystery to understanding.
What happens next?
They keep watching. They keep asking questions. They look for what's different about those two regions. They try to catch younger patients faster. And they wait for the biology to reveal itself.